Skip to main content
AUPH
NASDAQ Life Sciences

Aurinia Q2 2026: LUPKYNIS Sales Surge 19% to $79.4M, Net Income Hits $37.4M

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
8
Price
$15.75
Mkt Cap
$1.953B
52W Low
$10.34
52W High
$19.25
52W Position info
52% above low
Off High info
18% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

AUPH sits 52% above its 52-week low of $10.34.

Summary

Aurinia's Q2 2026 results show LUPKYNIS sales accelerating to $79.4M (+19% YoY), net income of $37.4M, and strong cash generation. The Kezar acquisition closed, and the balance sheet remains robust with $443M in cash and investments.


Key Events · Earnings and Guidance · AUPH

  • LUPKYNIS Sales Growth Accelerates

    Net product sales of $79.4M in Q2 2026, up 19% from $66.6M in Q2 2025, driven by deeper lupus nephritis market penetration.

  • Net Income More Than Doubles

    Net income of $37.4M ($0.28 diluted EPS) vs $21.5M ($0.16) in Q2 2025, reflecting revenue growth and operating expense discipline.

  • Cash Generation Strengthens

    Operating cash flow of $85.1M in H1 2026, up 87% YoY. Cash and investments totaled $443.1M at quarter-end, up from $398.0M at year-end 2025.

  • Kezar Acquisition Closed

    Completed acquisition of Kezar Life Sciences on May 11, 2026 for $55.5M total consideration, adding aritinercept pipeline and $23.1M in deferred tax benefits.


Analysis · AUPH · Life Sciences

Aurinia delivered a strong quarter with LUPKYNIS net product sales up 19% year-over-year to $79.4 million, driving total revenue to $83.2 million. Net income reached $37.4 million, a 74% increase from the prior year, as operating leverage improved. The company generated $85.1 million in operating cash flow in the first half, ending the quarter with $443.1 million in cash and investments. The acquisition of Kezar Life Sciences closed in May, adding a pipeline asset and deferred tax benefits. The results confirm the commercial momentum of LUPKYNIS and a strengthening financial position, though the normalized tax rate now reflects full cash tax payments going forward.

At the time of this filing, AUPH was trading at $15.75 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2B. The 52-week trading range was $10.34 to $19.25. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AUPH - Latest Insights

AUPH
Aug 06, 2026, 8:03 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $15.85
Real-time Price: $15.60 info
Change: -$0.2485 (-2%) info
Market Cap: $1.953B info
AUPH
Aug 06, 2026, 8:00 AM EDT
Source: Dow Jones Newswires
Importance Score:
8
Price at Filing: $15.75
Real-time Price: $15.60 info
Change: -$0.1499 (-0.95%) info
Market Cap: $1.953B info
AUPH
Jun 04, 2026, 6:44 PM EDT
Filing Type: SCHEDULE 13D/A
Importance Score:
8
Price at Filing: $16.36
Real-time Price: $15.60 info
Change: -$0.7599 (-5%) info
Market Cap: $1.953B info
AUPH
Jun 04, 2026, 7:07 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $15.82
Real-time Price: $15.60 info
Change: -$0.2182 (-1%) info
Market Cap: $1.953B info
AUPH
Jun 02, 2026, 9:54 PM EDT
Filing Type: 4
Importance Score:
8
Price at Filing: $15.39
Real-time Price: $15.60 info
Change: +$0.2101 (+1%) info
Market Cap: $1.953B info